News | September 24, 2025
Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
Relonchem receives marketing authorization for Moxonidine tablets
Relonchem receives marketing authorization for Moxonidine tablets
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The Subsidiary has received one inspectional observation in Form 483
Alkem Medtech to acquire 100% stake of Bombay Ortho
USFDA inspection at Emcure Pharmaceuticals API facility
Relonchem Limited has received Marketing Authorization for the product Levonorgestrel 1.5 mg Tablets from UK MHRA
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The orphan drug designation by the EC is issued for drugs which are intended to treat diseases that affect fewer than five in 10,000 people in the European Union
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Subscribe To Our Newsletter & Stay Updated
